June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
High Intensity Focused Ultrasound (HIFU) in patients with Refractory Glaucoma
Author Affiliations & Notes
  • Shlomo Melamed
    Goldschleger Eye Institute, Sheba Medical Center, Ramat Gan, Israel
  • Modi Goldenfeld
    Goldschleger Eye Institute, Sheba Medical Center, Ramat Gan, Israel
  • Daniel Cotlear
    Goldschleger Eye Institute, Sheba Medical Center, Ramat Gan, Israel
  • Alon Skaat
    Goldschleger Eye Institute, Sheba Medical Center, Ramat Gan, Israel
  • Footnotes
    Commercial Relationships Shlomo Melamed, Solx (F), Eyetechcare (F), Ioptima (F), Allergan (F); Modi Goldenfeld, None; Daniel Cotlear, None; Alon Skaat, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4744. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shlomo Melamed, Modi Goldenfeld, Daniel Cotlear, Alon Skaat; High Intensity Focused Ultrasound (HIFU) in patients with Refractory Glaucoma. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4744.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) in patients with Refractory Glaucoma.

Methods: Our study is a prospective study of 20 eyes of 20 patients with Refractory Glaucoma. HIFU is a new technology for Cyclophotocoagulation, utilizing a novel miniature probe with 6 piezoceramic transducers emitting ultrasound energy focused on the ciliary body and processes. All patients had an IOP of at least 30 mm Hg with maximally tolerated medical treatment and at least one invasive glaucoma surgery. All eyes were treated with HIFU delivered through 6 high-frequency transducers operating at 21 MHz and emitting for 6 seconds each. Complete Ophthalmic examination was performed before Rx and at 1 day, 1 week , 1, 3 and 6 months.

Results: Intraocular pressure was reduced by 42.6 % (P < 0.01) from a mean preoperative value of 36.4 ± 2.8 mm Hg to a mean postoperative value of 27.8 ± 4.3, 18.6 ± 3.6 and 20.9 ± 5.3 mm Hg at 1 day, 1 week and 3 months , respectively. No major intraoperative or postoperative complications were observed.

Conclusions: HIFU is a very safe and effective novel methodology for reducing IOP in Refractory Glaucoma cases.

Keywords: 455 ciliary body • 568 intraocular pressure  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×